BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Gramont A, Louvet C, André T, Tournigand C, Krulik M. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer. 1998;34:619-626. [PMID: 9713264 DOI: 10.1016/s0959-8049(97)00364-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Yeh KH, Yeh SH, Hsu CH, Wang TM, Ma IF, Cheng AL. Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. Br J Cancer. 2000;83:1510-1515. [PMID: 11076661 DOI: 10.1054/bjoc.2000.1456] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
2 Hsu C, Shen YC, Cheng CC, Cheng AL, Hu FC, Yeh KH. Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression. Gastric Cancer. 2012;15:265-280. [PMID: 22576708 DOI: 10.1007/s10120-012-0151-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
3 Sawdon AJ, Zhang J, Wang X, Peng CA. Enhanced Anticancer Activity of 5'-DFUR-PCL-MPEG Polymeric Prodrug Micelles Encapsulating Chemotherapeutic Drugs. Nanomaterials (Basel) 2018;8:E1041. [PMID: 30551585 DOI: 10.3390/nano8121041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
4 Deng YC, Zhen YS, Zheng S, Xue YC. Activity of boanmycin against colorectal cancer. World J Gastroenterol 2001; 7(1): 93-97 [PMID: 11819740 DOI: 10.3748/wjg.v7.i1.93] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lim YJ, Rhee JC, Bae YM, Chun WJ. Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. World J Gastroenterol 2007; 13(13): 1947-1952 [PMID: 17461495 DOI: 10.3748/wjg.v13.i13.1947] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
6 Zaanan A, Dalban C, Emile JF, Blons H, Fléjou JF, Goumard C, Istanbullu M, Calmel C, Alhazmi K, Validire P, Louvet C, de Gramont A, Laurent-Puig P, Taïeb J, Praz F. ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. J Cancer 2014;5:425-32. [PMID: 24847383 DOI: 10.7150/jca.8594] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
7 Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000;60:895-924. [PMID: 11085200 DOI: 10.2165/00003495-200060040-00005] [Cited by in Crossref: 135] [Cited by in F6Publishing: 125] [Article Influence: 6.8] [Reference Citation Analysis]
8 Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, Shiraishi Y, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Okamura N, Yamamori M, Tamura T, Sakaeda T. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011;8:210-5. [PMID: 21448307 DOI: 10.7150/ijms.8.210] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
9 Hsu C, Shen YC, Yang CH, Yeh KH, Lu YS, Hsu CH, Liu HT, Li CC, Chen JS, Wu CY, Cheng AL. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer 2004;90:1715-9. [PMID: 15150619 DOI: 10.1038/sj.bjc.6601796] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
10 Tamura T, Kuwahara A, Kadoyama K, Yamamori M, Nishiguchi K, Inokuma T, Takemoto Y, Chayahara N, Okuno T, Miki I, Fujishima Y, Sakaeda T. Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011;8:406-12. [PMID: 21750645 DOI: 10.7150/ijms.8.406] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
11 de Bono JS, Twelves CJ. The oral fluorinated pyrimidines. Invest New Drugs 2001;19:41-59. [PMID: 11291832 DOI: 10.1023/a:1006404701008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
12 Leonard P, Seymour MT, James R, Hochhauser D, Ledermann JA. Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 2002;87:1216-20. [PMID: 12439708 DOI: 10.1038/sj.bjc.6600641] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
13 Garde Noguera J, Jantus-Lewintre E, Gil-Raga M, Evgenyeva E, Maciá Escalante S, Llombart-Cussac A, Camps Herrero C. Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. Mol Clin Oncol 2017;6:403-8. [PMID: 28451421 DOI: 10.3892/mco.2017.1149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
14 Kim ST, Park KH, Shin SW, Kim YH. Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients? Cancer Res Treat 2014;46:48-54. [PMID: 24520223 DOI: 10.4143/crt.2014.46.1.48] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]